| Treatment of hyperkeratosis with Kerafoam emollient foam (30% urea) to assess effectiveness and safety within a clinical setting: a case study report. | |
| | |
MedLine Citation:
|
PMID: 18335652 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Ten patients enrolled in a single center, observational, prospective, open-label case study to assess the effectiveness and safety of a 28 day regimen with Kerafoam 30% urea emollient foam for treatment of hyperkeratosis. Clinician assessments of skin condition were recorded at baseline, day 14, and day 28. In addition, patients' ratings of the treatment impact on quality of life and skin condition, as well as overall satisfaction with the product were obtained. Key results demonstrated significant improvements in clinicians' ratings of skin condition at the day 14 and day 28 visits compared to baseline and significant improvements in patients' ratings of quality of life. No adverse events were reported and all patients completed the 28-day treatment regimen. Patient and clinician evaluations of the 30% urea emollient foam product were extremely favorable. |
| | |
Authors:
|
Jay A Goldstein; Ronald M Gurge |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of drugs in dermatology : JDD Volume: 7 ISSN: 1545-9616 ISO Abbreviation: J Drugs Dermatol Publication Date: 2008 Feb |
Date Detail:
|
Created Date: 2008-03-13 Completed Date: 2008-05-30 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101160020 Medline TA: J Drugs Dermatol Country: United States |
Other Details:
|
Languages: eng Pagination: 159-62 Citation Subset: IM |
Affiliation:
|
jaygoldsteinmd@aol.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Cutaneous Adult Aged Aged, 80 and over Dose-Response Relationship, Drug Drug Administration Schedule Emollients / administration & dosage, chemistry, therapeutic use* Female Humans Hyperkeratosis, Epidermolytic / drug therapy*, pathology Male Middle Aged Patient Satisfaction / statistics & numerical data Prospective Studies Quality of Life Severity of Illness Index Skin / drug effects*, pathology Time Factors Treatment Outcome Urea / administration & dosage, chemistry, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Emollients; 57-13-6/Urea |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Visible light photopatch testing of common photocontactants in female filipino adults with and witho...
Next Document: Case reports: lisinopril-induced erythroderma in an 85-year-old male.